{"analyses":[{"ciLowerLimit":"1.01","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.03","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.05","paramType":"Hazard Ratio (HR)","paramValue":"2.02","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"5.1","value":"4.3"},{"groupId":"OG001","lowerLimit":"3.2","upperLimit":"14.6","value":"7.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive trametinib PO QD on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Trametinib"},{"description":"Patients receive either A) leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 46-48 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity or B) capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Eligible and analyzable patients.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from registration","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}